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Abstract
The administration of paroxetine (0±5–8 mg}kg), a selective 5-HT reuptake inhibitor, induced a dose-
dependent reduction of exploratory activity of rats in the motility test. In the elevated plus-maze paroxetine
was less effective, only 8 mg}kg of paroxetine decreased the exploratory behaviour of rats. The doses of
paroxetine (2–8 mg}kg) reducing the exploratory activity in the motility test increased the density of CCK
receptors in the frontal cortex, but not in the hippocampus. The treatment of rats with the CCK
B
receptor
antagonist LY288,513 (0±01–1 mg}kg) did not change the exploratory activity. However, the reduction of
exploratory activity induced by the low dose of paroxetine (2 mg}kg), but not by the higher dose (8 mg}kg),
was dose-dependently reversed by the administration of LY288,513. Moreover, LY288,513 did not affect the
anti-exploratory action of paroxetine (8 mg}kg) in the elevated plus-maze. Diazepam at doses (0±5–1±0 mg}kg)
not suppressing the locomotor activity did not change the anti-exploratory action of paroxetine in the motility
test. It is likely that the anti-exploratory action of a low dose of paroxetine (2 mg}kg) is not related to the
increase in anxiety, but rather to the reduction of exploratory drive. Evidence exists that this effect of
paroxetine is mediated via the activation of CCK-ergic transmission.
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Introduction
There is a growing body of evidence that cholecystokinin
(CCK) and 5-hydroxytryptamine (5-HT) interact in the
regulation of behaviour. The administration of chole-




) receptors, induces an anxiogenic-
like action in the elevated plus-maze, and this behavioural
action of CCK agonist is accompanied by the increased
release of 5-HT in the cerebral cortex (Rex et al., 1994).
On the other hand, CCK
B
receptor antagonist L365,260
causes the opposite effect and antagonizes the behavioural
and neurochemical action of CCK-4 (Rex et al., 1994).
Peripherally administered CCK-8 reduces the food intake
and elevates the levels of 5-HT in the hypothalamus
(Voigt et al., 1998). The stimulation of somatodendritic 5-
HT autoreceptors by 5-HT
"A
receptor agonist 8-OH-
DPAT reverses CCK-8 induced satiety and CCK-4 caused
anxiety (Poeschla et al., 1992 ; Rex et al., 1997). However,
it should be noted that the anxiogenic-like action of CCK
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) receptors are respon-
sible for CCK-induced satiety (Shlik et al., 1997). The
application of CCK-4 to the brain membranes increases
the density of 5-hydroxytryptamine 5-HT
#
receptors in
the frontal cortex (Agnati et al., 1983). Therefore, it is not
surprising that the 5-HT
#
receptor antagonist deramci-





receptor agonist (Gacsalyi et
al., 1997).
However most experiments have studied a role of 5-
HT in the action of CCK receptor agonists and antago-
nists, whereas very little attention is paid to the opposite
interaction. Nevertheless, it has been shown that 5-HT
can increase the release of CCK in the cerebral cortex and
nucleus accumbens (Raiteri et al., 1993). The acute
administration of alaproclate, the 5-HT reuptake inhibitor,
significantly elevates the levels of CCK in the cingulate
cortex and periaquaductal grey (Rose! n et al., 1995).
Moreover, the exposure of rats to the novel aversive
environment clearly increases the release of 5-HT in the
frontal cortex and hippocampus (File et al., 1993 ; Rex et
al., 1994). The administration of fluoxetine, the 5-HT
reuptake inhibitor, dose-dependently reduces the ex-
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(Handley and McBlane, 1993). Handley and McBlane
(1993) have considered the anti-exploratory action of
fluoxetine as the anxiogenic-like action. Den Boer and
Westenberg (1996) have shown in the clinical studies that
the acute administration of 5-HT reuptake inhibitors may
increase anxiety in patients suffering from anxiety
disorders. Therefore, the aim of present experiments was
to clarify a possible role of CCK in the anxiogenic-like
action of drugs increasing 5-HT-ergic transmission. For
that purpose a selective 5-HT reuptake inhibitor par-
oxetine was chosen. The behavioural effects of paroxetine
were analysed in the motility box and elevated plus-maze.
These two behavioural tests were selected to distinguish
whether paroxetine-induced inhibition of exploratory
behaviour is due to the increase in anxiety or the reduction
of exploratory drive. Moreover, the action of paroxetine
was studied on the parameters of CCK binding in the
frontal cortex and hippocampus. Also the influence of
CCK
B
antagonist LY288,513 and diazepam, a benzo-




Male Wistar (Han}Kuo) rats (National Animal Centre,
Kuopio, Finland) weighing 200–220 g were kept in the
animal house at 20³2 °C in a 12-h light}dark cycle (light
on at 07 :00 hours). Tap water and food pellets were
available ad libitum. All animal procedures were approved
by University of Tartu Animal Care Committee in
accordance with the European Communities Directive of
24 November 1986 (86}609}EEC). The animals were
kept in the animal house at least 2 wk before the beginning
of experiment.
Materials
Paroxetine, a selective 5-HT reuptake inhibitor, was
provided by SmithKline Beecham (UK). LY288,513
[trans-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazo-
lidinecarboxamide], an antagonist of CCK
B
receptor, was
kindly donated by Eli Lilly & Co. (USA). Paroxetine was
dissolved in saline, whereas LY288,513 and diazepam
(Sigma, USA) were suspended in 1% Tween-80 (Ferak,
Germany) solution in saline. [Propionyl-$H]propionyl-
ated-CCK-8-sulphated ([$H]pCCK-8) was obtained from
Amersham Radiochemicals (UK). The other chemicals for




, KCl and EDTA ([ethylenediamine-tetra-
acetic acid]) were purchased from Sigma (USA).
Behavioural testing
The animals were brought into the experimental room 1 h
before the experiment. The rats were new to handling and
were not adapted to the experimental situation. Each rat
was used only once. All experiments were carried out
between 14 :00 and 19 :00 hours. Paroxetine, diazepam
and LY288,513 were given 30 min before the beginning
of studies.
Motility test
Exploratory activity of rats was measured by means of
photoelectric motility boxes (448¬448¬450 mm) con-
nected to a computer (TSE Technical & Scientific Equip-
ment GmbH, Germany). Animals, new to the test situation
were placed singly into the apparatus. Time in exploration
(s), distance of exploration (in metres), number and
duration of rearing were registered in 5-min intervals
during the 15-min observation period.
Elevated plus-maze
The method initially suggested by Handley and Mithani
(1984) for the measurement of exploratory activity was
employed in rats with some modifications (Pellow et al.,
1985). The apparatus consisted of two opposite open
arms (50¬10 cm) without side walls and two enclosed
arms (50¬10¬40 cm) with side walls and end wall,
extending from a central square (10¬10 cm). The maze
was elevated to the height of 50 cm, and placed in a lit
room. During a 5 min observation session the following
measures were taken by an observer : (1) time spent in
exploring of open part (central square and open arms) of
plus-maze ; (2) time spent in open arm; (3) number of
closed and open arm entries ; (4) number of line crossings
in open part ; and (5) ratio between open and total arm
entries. At the beginning of experiment an animal was
placed into the centre of plus-maze, facing towards a
closed arm. An arm entry was counted only when all four
limbs of the rat were within a given arm.
[3H]pCCK-8 binding assay
The animals were decapitated 30 min after the injection of
various doses of paroxetine (0±5–16 mg}kg i.p.). After
decapitation the brains were quickly dissected on ice. The
binding studies were performed in the frontal cortex (also
containing the anterior cingulate and frontoparietal cor-
tex) and hippocampus. These brain structures were
selected according to previous studies since the most
prominent neurochemical changes due to the reduced
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Figure 1. The effect of paroxetine (0±5–8 mg}kg), diazepam (0±5–2±5 mg}kg) and LY288,513 (0±01–1 mg}kg) on the exploratory
activity of rat in the motility box. * p! 0±05 compared to saline (paroxetine) or vehicle-treated (LY288,513, diazepam) rats,
Tukey HSD test after the significant one-way ANOVA). Vehicle for LY288,513 and diazepam was 1% Tween-80 solution in
saline.
regions (File et al., 1993 ; Harro et al., 1995 ; Ko4 ks et al.,
1997 ; Rex et al., 1994). Brain tissues were homogenized in
20 volumes of ice-cold 50 m Tris-HCl (pH 7±4 at 4 °C)
using a Potter-S glass-Teflon homogenizer (1000 rpm, 12
passes). The membranes were washed twice in the same
buffer by centrifugation (48000 g for 20 min) and re-
suspension. After the last centrifugation, the crude brain
membranes were homogenized in Hepes buffer (10 m
Hepes ; 130 m NaCl ; 5 m KCl ; 1 m MgCl
#
; 1 m
EDTA; pH 6±5 adjusted with 1  NaOH) containing
bovine serum albumin (0±5 mg}ml). The parameters of
CCK receptors were determined in the presence of
0±05–2±4 n [$H]pCCK-8 (specific activity 79 Ci}mmol)
at 23 °C in a total incubation volume of 0±5 ml. Caerulein
(100 n) was added to determine the nonspecific binding.
The incubation was terminated after 120 min by the rapid
filtration over Whatman GF}B filters presoaked with the
bovine serum albumin (0±5 mg}ml). The filters were
washed with 3¬3 ml of ice-cold Hepes buffer. In the
separate study paroxetine (0±01–1 m) was added to the
incubation medium to reveal the direct interaction of
paroxetine with CCK-binding sites in the cerebral cor-
tex. The protein content was measured according to a
dye-binding assay (Bradford, 1976). Saturation curves
were analysed using nonlinear least squares regression
(Leatherbarrow, 1987).
Statistics
Results are expressed as mean values³... The be-
havioural studies were analysed using one-way analysis
of variance (ANOVA). Post hoc comparisons between
individual groups were performed by means of Tukey
HSD test using the Statistica for Windows software. The
data of radioligand-binding experiments were assessed by
means of Student’s t test.
Results
The administration of paroxetine (0±5, 2, 4, 8 mg}kg)
induced a dose-dependent reduction of exploratory
activity of rats in the motility test (Figure 1). Paroxetine
significantly reduced the frequency of rearing (F
%,&"
¯
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Figure 2. The effect of paroxetine (0±5–16 mg}kg) on the
parameters of CCK binding in the frontal cortex and
hippocampus. K
d
, dissociation constant in n ; B
max
, the
apparent number of binding sites in fmol}mg protein.
* p! 0±05 (compared to saline-treated rats, Student’s t test).

















Saline 124³13 24³2±7 1±6³0±5 18³6 6±0³0±5 18³5
Paroxetine
(0±5 mg}kg)
114³18 21³3±8 1±4³0±3 21³5 5±1³0±9 19³4
Paroxetine
(2 mg}kg)
131³17 25³5±5 1±3³0±6 19³9 6±0³1±2 10³4
Paroxetine
(4 mg}kg)
114³15 19³3±9 1±3³0±7 13³8 4±4³0±7 12³7
Paroxetine
(8 mg}kg)
66³16* 8³1±9* 0±3³0±3 4³3 1±9³0±4* 6³4
Paroxetine
(16 mg}kg)
85³13 14³4 0±5³0±4 18³13 4±0³1±2 7³5
* p! 0±05 (Tukey HSD test after the significant one-way ANOVA, compared to saline-treated rats).
p! 0±05). Paroxetine also tended to inhibit the other
parameters of exploratory activity in the motility test.
However, these changes were not statistically significant.
The same doses of paroxetine tended to elevate the
density of CCK-binding sites in the frontal cortex (also
including the cingulate and frontoparietal cortex), but not
in the hippocampus (Figure 2). The addition of paroxetine
(0±01–1 m) to the brain membranes did not modify CCK
binding in the cerebral cortex (data not shown). Dif-
ferently from the motility test, only 8 mg}kg of par-
oxetine inhibited the exploratory behaviour of rats in
the elevated plus-maze. Paroxetine decreased time spent
in open part (F
&,%$
¯ 2±63, p! 0±05), number of line
crossings (F
&,%$
¯ 2±97, p! 0±05) and closed arm entries
(F
&,%$
¯ 3±18, p! 0±05) (Table 1).
LY288,513 (0±01–1 mg}kg), a CCK
B
receptor antag-
onist, did not affect the behaviour of rats in the motility
test (Figure 1). Nevertheless, the pretreatment of rats with
LY288,513 dose-dependently antagonized the anti-
exploratory action of paroxetine (2 mg}kg ; time in
locomotion F
%,$&
¯ 2±8, p! 0±05 ; frequency of rearing
F
%,$&
¯ 3±83, p! 0±05 ; time in rearing F
%,$&
¯ 4±13,
p! 0±01) (Figure 3). The combination of CCK
B
receptor
antagonist with the higher dose of paroxetine (8 mg}kg)
did not reverse the behavioural suppression induced by
5-HT reuptake inhibitor (Figure 4). In addition, LY288,513
(0±01–1 mg}kg) did not antagonize the anti-exploratory
action of paroxetine (8 mg}kg) in the elevated plus-maze
(data not shown).
The administration of the benzodiazepine agonist
diazepam (0±5–2±5 mg}kg) also suppressed the explora-
tory activity of rats at the highest dose (2±5 mg}kg)
(Figure 1, time spent in exploration F
$,$#
¯ 3±33, p!
0±05 ; the exploration distance F
$,$#
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Figure 3. The effect of LY288,513 (0±01–1 mg}kg) on the anti-exploratory action of paroxetine (2 mg}kg). * p! 0±05 (compared
to saline­vehicle-treated rats) ; ­, p! 0±05 (compared to paroxetine-treated rats, Tukey HSD test after the significant one-way
ANOVA). CONT, saline­vehicle-treated rats ; PRX2, paroxetine 2 mg}kg ; LY, LY288,513.
However, the combination of diazepam at doses not
suppressing exploratory behaviour (0±5–1±0 mg}kg) with
paroxetine (2 mg}kg) did not modify the anti-exploratory
action of 5-HT reuptake inhibitor (Figure 5).
Discussion
The administration of paroxetine, a selective inhibitor of
5-HT reuptake, induced a significant suppression of
exploratory activity of rats in the motility test. Already
2 mg}kg of paroxetine inhibited the frequency of rearing
and time spent in rearing. However, the selectivity of
paroxetine in inhibition of rearing depends on the basal
exploratory activity of control animals. In the experiments
where the activity of rats was higher, this dose of
paroxetine also reduced the other parameters of ex-
ploratory behaviour, namely time spent in exploration
and distance of exploration. Nevertheless, the frequency
of rearing and time spent in rearing are the most sensitive
parameters in revealing the anti-exploratory action of
paroxetine in the motility test. Moreover, paroxetine was
apparently less potent in the reduction of exploratory
activity of rats in the elevated plus-maze. Only 8 mg}kg
of paroxetine decreased the exploratory behaviour of
animals. The anti-exploratory action of paroxetine in the
elevated plus-maze was accompanied by the decreased
number of closed arm entries, reflecting the suppression of
locomotor activity. The existing experimental data sup-
port the role of 5-HT in the regulation of anxiety.
Handley and McBlane (1993) have shown that the
administration of fluoxetine, the 5-HT reuptake inhibitor,
induces the anxiogenic-like action in the rat elevated plus-
maze. The administration of paroxetine produced an
anxiogenic-like profile in the rat two-compartment ex-
ploration test (Sanchez and Meier, 1997). The exposure of
rats to the aversive environment clearly increases the
release of 5-HT in the frontal cortex and hippocampus
(File et al., 1993 ; Rex et al., 1994). Nevertheless, the
present behavioural study is in disagreement with the
data since the anti-exploratory action of paroxetine is
related to the decrease of exploratory drive rather than to
the increase in anxiety.
Rose! n et al. (1995) have shown that 5-HT reuptake
inhibitor alaproclate increases the levels of CCK in the
cingulate cortex and periaquaductal grey. The direct
application of 5-HT to the neurons of cerebral cortex and
nucleus accumbens evoked the release of CCK (Raiteri et
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Figure 4. The effect of LY288,513 (0±01–1 mg}kg) on the anti-exploratory action of paroxetine (8 mg}kg). * p! 0±05 (compared
to saline­vehicle-treated rats, Tukey HSD test after the significant one-way ANOVA). CONT, saline­vehicle-treated rats ;
PRX8, paroxetine 8 mg}kg ; LY, LY288,513.
number of CCK-binding sites in the frontal cortex, but not
in the hippocampus. The stressful manipulations in rats
are shown to increase the density of CCK receptors and
mRNA levels of preproCCK in the frontal cortex (Harro
et al., 1995 ; Pratt and Brett, 1995). The social isolation of
rats for 7 d induced an anxiogenic-like action and elevated
the number of CCK receptors in the frontal cortex, but not
in the hippocampus (Vasar et al., 1993). Therefore, it is not
surprising that the pretreatment of rats with the CCK
B
receptor antagonist LY288,513 dose-dependently re-
versed the anti-exploratory action of paroxetine
(2 mg}kg). This in line with the study of Matto et al.
(1996) showing the ability of the CCK
B
receptor an-
tagonist L365,260 to antagonize the anti-exploratory
effect of the 5-HT reuptake inhibitor citalopram in the
elevated plus-maze. The data support the hypothesis that
the administration of 5-HT reuptake inhibitors increases
CCK-mediated neurotransmission in the brain. The anta-
gonism of LY288,513 against paroxetine seems to be a
specific since the CCK
B
receptor antagonist does not
increase the exploratory activity per se. Nevertheless,
LY288,513 did not block the effect of the higher dose of
paroxetine (8 mg}kg) showing a difference in the action
of two doses of 5-HT reuptake inhibitor. This discrepancy
could be explained by the fact that paroxetine at higher
doses induces a more pronounced increase in the con-
centration of 5-HT in the synaptic cleft, masking a
possible interaction of a drug with CCK. Differing from
the present study, Harro et al. (1997) did not find changes
in the density of CCK receptors or in the content of CCK-
related peptides after long-term treatment with various
antidepressant drugs, including 5-HT reuptake inhibitors.
However, they analysed the action of long-term admin-
istration of antidepressant drugs, whereas the effect of
acute treatment was not examined.
In conclusion, the selective serotonin reuptake inhibitor
paroxetine induces a clear anti-exploratory effect in the
motility boxes. However, the above-described be-
havioural studies do not reflect the increase in anxiety
after the acute treatment with paroxetine. This statement
is supported by the findings that paroxetine did not cause
the anxiogenic-like action in the elevated plus-maze and
that diazepam, a potent anxiolytic drug, did not antag-
onize the anti-exploratory action of paroxetine in the
motility test. Therefore, it is likely that paroxetine reduces
the exploratory drive in rats. This effect of paroxetine
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Figure 5. The effect of diazepam (0±5–2±5 mg}kg) on the anti-exploratory action of paroxetine (2 mg}kg). * p! 0±05 (compared
to saline­vehicle-treated rats, Tukey HSD test after the significant one-way ANOVA). CONT, saline­vehicle-treated rats ;
PRX2, paroxetine 2 mg}kg ; DIA, diazepam.
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